Chinanews client, Beijing, December 15th (Reporter Zhang Ni) At present, the national centralized drug procurement has been carried out for more than three years.
On the one hand, the price of selected drugs has dropped significantly, bringing real benefits to patients.
On the other hand, the outside world is also concerned about the situation of the unselected drugs, especially the original research drugs?
Have there been any significant changes in their prices and purchases?
The answer may be found in a set of data released by the China Medical Insurance Research Association a few days ago.
Data map: Zhejiang Anji automatic medicine dispenser "on duty" photo by Yu Danfei
Obvious "replacement effect" of selected generic drugs
On the 15th, the "China Medical Insurance" magazine held a press conference in Beijing on "Changes in the use of unselected original research drugs in centralized procurement-the use of "two reductions and one increase" and the price "three prices all fall"" press conference.
It was introduced at the meeting that the China Medical Insurance Research Association selected 9 drugs including atorvastatin oral regular-release dosage form and amlodipine oral regular-release dosage form. Based on incomplete statistics on the national situation, the results of centralized procurement were compared one year before and after the implementation. Price and purchase volume situation.
The data shows that from the perspective of drug purchases, the purchase of unselected original research drugs has been greatly reduced, and the selected generic drugs have a significant "substitution effect" on the unselected original drugs.
One year after the implementation of the centralized procurement results, the total national annual purchases of unselected original research drugs decreased by an average of 46% compared with the year before the implementation of the centralized procurement results.
Among them, simvastatin oral regular-release dosage form has the largest decrease, reaching 74.4%; followed by hydromagnesium carbonate chewable tablets, with a decrease of 60.3%; again, valsartan oral regular-release dosage form, with a decrease of 55%; Imma, which has the least decrease The oral regular-release dosage form of tinib also reached 13.4%.
The total annual purchases of unselected generic drugs fell by 80.8%, 9 drugs fell by more than 70%, and 6 drugs fell by more than 80%.
Among them, atorvastatin oral regular-release dosage form has the largest decrease, reaching 94.9%.
In contrast, the total annual purchases of generic drugs selected by the selected generic drugs increased by 265.2%. Among them, omeprazole oral normal-release formulations increased the most, reaching 522.6%; followed by amlodipine oral normal-release formulations, with an increase of 506.5%; Imatinib's oral regular-release dose, with the smallest increase, also reached 54.5%.
Data map: People line up for registration in the outpatient building of a hospital.
Photo by China News Agency reporter Yin Liqin
Price cuts for those who fail to choose! Reduce the burden of medication use by the masses
It is worth mentioning that the study also shows that under the same generic name, the original research drugs, the selected generic drugs and the unselected generic drugs have "all the three prices", and the burden of drugs for the masses has been significantly reduced.
Among them, the price of selected generic drugs has fallen most significantly.
The effect of "quantity-for-price" in centralized procurement was obvious. The average price of nine selected generic drugs dropped by 82.4%. Among them, entecavir oral normal-release dosage form dropped the most, reaching 90.1%, followed by atorvastatin oral constant-release dosage form, which dropped by up to 82.4%. 83.1%.
The oral regular-release dosage form of imatinib, with the least decrease, also reached 21.8%.
In addition, according to the price decline of selected generic drugs, various medical insurance departments have jointly lowered the prices of corresponding non-selected original research drugs, or anchored the national minimum price, or anchored the purchase price in Shanghai to guide the price of non-selected original research drugs to decline.
The non-selected original research drugs of the 9 drugs fell by an average of 12.9%.
Among them, the oral regular-release dosage form of valsartan has the largest drop, reaching 20.8%; the second is the oral regular-release dosage form of atorvastatin, which has a drop of 20.7%; again, the oral regular-release dosage form of rosuvastatin has a drop of 19.0%.
The lowest drop of hydromagnesium carbonate chewable tablets also reached 6.5%.
The prices of unselected generic drugs also fell.
The average decline of the nine unselected generic drugs was 17.4%.
Among them, entecavir oral regular-release dosage form decreased the most, reaching 34.3%; followed by simvastatin oral regular-release dosage form, with a decrease of 19.9%; again, imatinib oral regular-release dosage form, with a decrease of 18.3%.
Chewable hydromagnesium carbonate tablets, which had the least decrease, also reached 3.4%.
It was introduced at the meeting that the effect of price cuts will continue to be released in 2021.
Compared with the first year after the implementation of the centralized procurement results, the average drug price in 2021 will drop by 25.7%, of which the selected drugs will drop by an average of 29.1%.
In addition, the selected generic drugs continue to replace the unselected original research drugs and the unselected generic drugs, and the "generic drug substitution" effect continues to strengthen.
Compared with the first year after the implementation of the centralized procurement results, the market share of selected generic drugs in 2021 will further increase to 84.4%, an increase of 5.2%; the market share of original research drugs will further drop to 11.7%, a decrease of 3.9%; the selected generic drugs of each drug The market share is more than 80%, and the three drugs have reached more than 90%.
(Finish)